STAAR Surgical reported third-quarter 2026 net sales of $83.4 million, a 12% decrease from the prior-year period which included $25.9 million of previously deferred China sales. Excluding that impact, sales grew 21%. Net income was $5.6 million, or $0.11 per diluted share, compared to $8.9 million in the prior year. Adjusted EBITDA was $14.4 million, or $0.28 per diluted share. The company also announced that its Board authorized a new $50 million share repurchase program. STAAR Surgical is the global leader in implantable phakic intraocular lenses for vision correction.
